Investigational Studies

LONDON and CARLSBAD, Calif., Sept. 27, 2018 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that EPIDIOLEX® (cannabidiol) oral solution has been transferred […]

by

Product expected to be available within six weeks LONDON and CARLSBAD, Calif., Sept. 27, 2018 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today […]

by

SAN DIEGO, CA, Sept. 27, 2018 (GLOBE NEWSWIRE) — Emerald Health Pharmaceuticals Inc. (EHP), a company developing medicines based on cannabinoid science, today announced the initiation of enrollment of its Phase I clinical trial of EHP-101, an oral formulation of a patented, synthetic new chemical entity (NCE) derived from cannabidiol (CBD) and chemically modified to […]

by

The faces of Dravet Syndrome.What Does the Ruling Mean for Most School Districts Nationwide? It appears that many individual school districts, especially in medical marijuana-approved states, will now be forced to suddenly begin the evaluation process of whether districts will have to allow the new prescription pharmaceutical to be used on school grounds and buses. […]

by

CBD oil. (Credit: ELRoi/Shutterstock) One of the most controversial drugs in America can’t even get you high. Derived from marijuana, CBD, or cannabidiol, could help treat a range of medical conditions, early research suggests — but its Schedule I status has made it hard to study, leaving researchers and patients in the dark. Although it’s […]

by

CBD oil. (Credit: ELRoi/Shutterstock) One of the most controversial drugs in America can’t even get you high. Derived from marijuana, CBD, or cannabidiol, could help treat a range of medical conditions, early research suggests — but its Schedule I status has made it hard to study, leaving researchers and patients in the dark. Although it’s […]

by

TORONTO, Sept. 11, 2018 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (TSX VENTURE: RVV) (OTCQB: RVVTF) (FSE: 31R) (“Revive” or the “Company”), a specialty cannabis company focused on the research, development and commercialization of novel cannabinoid-based products, today announced the introduction of RELICANN™, the Company’s hemp-based  and medical cannabis brand designed for the health and wellness […]

by

TORONTO – September 11, 2018 (Investorideas.com Newswire) Revive Therapeutics Ltd. (TSX VENTURE: RVV) (OTCQB: RVVTF) (FSE: 31R) (“Revive” or the “Company”), a specialty cannabis company focused on the research, development and commercialization of novel cannabinoid-based products, today announced the introduction of RELICANN™, the Company’s hemp-based and medical cannabis brand designed for the health and wellness […]

by

TORONTO, Sept. 05, 2018 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (TSX VENTURE: RVV) (OTCQB: RVVTF) (FSE: 31R) (“Revive” or the “Company”), a specialty cannabis company focused on the research, development and commercialization of novel cannabis-based products, is pleased to provide an update on its cannabis-based pharmaceuticals initiatives in its objective in offering novel therapies for […]

by

TORONTO, Sept. 05, 2018 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (TSX VENTURE: RVV) (OTCQB: RVVTF) (FSE: 31R) (“Revive” or the “Company”), a specialty cannabis company focused on the research, development and commercialization of novel cannabis-based products, is pleased to provide an update on its cannabis-based pharmaceuticals initiatives in its objective in offering novel therapies for […]

by

TORONTO, Aug. 22, 2018 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (TSX VENTURE:RVV) (OTCQB:RVVTF) (FSE:31R) (“Revive” or the “Company”), a specialty medical cannabis company, today announced that it has submitted an application to the U.S. Food and Drug Administration (“FDA”) seeking orphan drug designation of cannabidiol (“CBD”) for the treatment of hepatic ischemia and reperfusion injury (“IRI”) during liver […]

by

Cannabis world domination.Sara Brittany Somerset As the marijuana business grows globally, many stock watchers and research analysts are making predictions about where the most significant investment opportunities are. Investment site The Motley Fool recently published an analysis by Keith Speights of forecasts for the 2022 marijuana market. A lot can happen even monthly in the ever-evolving […]

by

TORONTO, Aug. 28, 2018 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (TSX VENTURE: RVV) (OTCQB: RVVTF) (FSE: 31R) (“Reviveâ€� or the “Companyâ€�), a specialty cannabis company focused on the research, development and commercialization of novel cannabinoid-based products, is pleased to provide a corporate update on its product strategy and business development activities in its objective in […]

by

TORONTO, Aug. 28, 2018 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (TSX VENTURE: RVV) (OTCQB: RVVTF) (FSE: 31R) (“Reviveâ€� or the “Companyâ€�), a specialty cannabis company focused on the research, development and commercialization of novel cannabinoid-based products, is pleased to provide a corporate update on its product strategy and business development activities in its objective in […]

by

TORONTO, Aug. 22, 2018 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (TSX VENTURE:RVV) (OTCQB:RVVTF) (FSE:31R) (“Revive” or the “Company”), a specialty medical cannabis company, today announced that it has submitted an application to the U.S. Food and Drug Administration (“FDA”) seeking orphan drug designation of cannabidiol (“CBD”) for the treatment of hepatic ischemia and reperfusion injury […]

by